Clinical Ink, a global clinical trial technology company, has appointed CCO Chris Crucitti, COO Brian Donahue, and VP Project Operations Bill Barrasso. All three positions are newly created to help manage the company’s eCOA, ePRO+, DDC, and eConsent platform.   “Clinical Ink pioneered the development of decentralized trials (eSource) long before the label even existed and we are responding to the tremendous growth opportunities ahead,” said Clinical Ink CEO, Ed Seguine. “This industry is plagu...